Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations
暂无分享,去创建一个
[1] N J Welton,et al. A Bayesian approach to analysing the cost-effectiveness of two primary care interventions aimed at improving attendance for breast screening. , 2006, Health economics.
[2] D. Moher,et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.
[3] Sarah Darby,et al. Lung cancer deaths from indoor radon and the cost effectiveness and potential of policies to reduce them , 2009, BMJ : British Medical Journal.
[4] Richard F. Gunst,et al. Regression and ANOVA: An Integrated Approach Using SAS Software , 2003, Technometrics.
[5] Frank A. Sloan,et al. Valuing health care : costs, benefits, and effectiveness of pharmaceuticals and other medical technologies , 1995 .
[6] W. Manning. Dealing with Skewed Data on Costs and Expenditures , 2006 .
[7] M. Johannesson,et al. Theory and methods of economic evaluation of health care. , 1996, Developments in health economics and public policy.
[8] Douglas G Altman,et al. Analysis and reporting of factorial trials: a systematic review. , 2003, JAMA.
[9] Martin J Buxton,et al. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. , 2003, Health economics.
[10] D. Couper,et al. Factorial designs in clinical trials: options for combination treatment studies. , 2005, Journal of studies on alcohol. Supplement.
[11] M. Sculpher,et al. Decision Modelling for Health Economic Evaluation , 2006 .
[12] Karl Claxton,et al. The Value of Heterogeneity for Cost-Effectiveness Subgroup Analysis , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.
[13] S. Jowett,et al. Joint protection and hand exercises for hand osteoarthritis: an economic evaluation comparing methods for the analysis of factorial trials , 2014, Rheumatology.
[14] David Moher,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[15] A Briggs,et al. Economic evaluation and clinical trials: size matters , 2000, BMJ : British Medical Journal.
[16] P. Clarke,et al. Comprar Applied Methods of Cost-effectiveness Analysis in Healthcare | Alastair M. Gray | 9780199227280 | Oxford University Press , 2010 .
[17] S. Piantadosi,et al. Factorial designs for randomized clinical trials. , 1985, Cancer treatment reports.
[18] M. Sculpher,et al. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. , 2005, Health economics.
[19] P. Dolan,et al. Modeling valuations for EuroQol health states. , 1997, Medical care.
[20] Milton C. Weinstein,et al. Valuing health care: From cost–effectiveness ratios to resource allocation: where to draw the line? , 1995 .
[21] M. Johannesson,et al. Cost-utility analysis from a societal perspective. , 1997, Health policy.
[22] Andrew R Willan,et al. The value of information and optimal clinical trial design , 2005, Statistics in medicine.
[23] R Simon,et al. Bayesian design and analysis of two x two factorial clinical trials. , 1997, Biometrics.
[24] Ilias Goranitis,et al. Economic evaluation alongside factorial trials: a systematic review of empirical studies. , 2015, Expert review of pharmacoeconomics & outcomes research.
[25] Stephanie Green,et al. Factorial Designs with Time-to-Event Endpoints , 2012 .
[26] M Johannesson,et al. On the decision rules of cost-effectiveness analysis. , 1993, Journal of health economics.
[27] L. Gluud,et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. , 2008, The Cochrane database of systematic reviews.
[28] A. Briggs,et al. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. , 2002, Health economics.
[29] M. Boyle,et al. Multiattribute and Single‐Attribute Utility Functions for the Health Utilities Index Mark 3 System , 2002, Medical care.
[30] Andrew Briggs,et al. Statistical Analysis of Cost-Effectiveness Data , 2006 .
[31] Sally Hopewell,et al. The quality of reports of randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed , 2010, BMJ : British Medical Journal.
[32] R. Willke,et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[33] S. Kenyon,et al. Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial , 2008, The Lancet.
[34] Per Capita,et al. About the authors , 1995, Machine Vision and Applications.
[35] S. Wilson. Methods for the economic evaluation of health care programmes , 1987 .
[36] T J Ulahannan,et al. Decision Making in Health and Medicine: Integrating Evidence and Values , 2002 .
[37] K Claxton,et al. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.
[38] R T O'Neill,et al. Efficacy evaluation for monotherapies in two-by-two factorial trials. , 1995, Biometrics.
[39] S. Thompson,et al. Multiple regression of cost data: use of generalised linear models , 2004, Journal of health services research & policy.
[40] M. Weinstein,et al. Foundations of cost-effectiveness analysis for health and medical practices. , 1977, The New England journal of medicine.
[41] A. Briggs,et al. Statistical Analysis of Cost-effectiveness Data: Willan/Statistical Analysis of Cost-effectiveness Data , 2006 .
[42] Grazyna Adamiak,et al. Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .
[43] Deborah M Caldwell,et al. Research prioritization based on expected value of partial perfect information: a case‐study on interventions to increase uptake of breast cancer screening , 2008 .
[44] Andrew R Willan,et al. Expected value of information and decision making in HTA. , 2007, Health economics.
[45] R. Grieve,et al. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared. , 2010, Health economics.
[46] S. Pocock,et al. Factorial trials in cardiology: pros and cons. , 1994, European heart journal.
[47] J. Wittes,et al. Factorial designs in clinical trials: the effects of non-compliance and subadditivity. , 1989, Statistics in medicine.
[48] Andrew R Willan,et al. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. , 2004, Health economics.
[49] D P Byar. Factorial and reciprocal control designs. , 1990, Statistics in medicine.
[50] Tie-Hua Ng,et al. The impact of a preliminary test for interaction in a 2 × 2 factorial trial , 1994 .
[51] Andrew Briggs,et al. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people , 2006, BMJ : British Medical Journal.
[52] Jalpa A Doshi,et al. Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[53] Stavros Petrou,et al. Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting , 2011, BMJ : British Medical Journal.
[54] Simon G Thompson,et al. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. , 2005, Health economics.
[55] Sarah Wordsworth,et al. Applied Methods of Cost-Effectiveness Analysis in Healthcare , 2010 .
[56] Alan A Montgomery,et al. Design, analysis and presentation of factorial randomised controlled trials , 2003, BMC medical research methodology.
[57] Andrea Manca,et al. Regression Estimators for Generic Health-Related Quality of Life and Quality-Adjusted Life Years , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[58] D. Moher,et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2011, BMJ : British Medical Journal.
[59] S. Bryan,et al. Incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods , 2012, Trials.
[60] Stephen S. Lim,et al. Methods to assess the costs and health effects of interventions for improving health in developing countries , 2005, BMJ : British Medical Journal.
[61] C. Silagy,et al. Review of 39 years of randomized controlled trials in the British Journal of General Practice. , 1994, The British journal of general practice : the journal of the Royal College of General Practitioners.
[62] Andrew Thomas,et al. WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility , 2000, Stat. Comput..
[63] A Briggs,et al. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. , 1998, Health economics.
[64] H M Hung. Two-stage tests for studying monotherapy and combination therapy in two-by-two factorial trials. , 1993, Statistics in medicine.
[65] M. Sculpher,et al. Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.
[66] D. Purdie. Statistical Methods in Medical Research, 4th edn , 2003 .
[67] A H Briggs,et al. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.
[68] Rory A. Fisher,et al. The Arrangement of Field Experiments , 1992 .
[69] M. Drummond,et al. Whither trial-based economic evaluation for health care decision making? , 2006, Health economics.
[70] A. Rothberg. Making Choices in Health: WHO Guide to Cost Effectiveness Analysis , 2008 .
[71] Roberta Ara,et al. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.